top of page

Why Slenyto® ?


Slenyto® Clinical Evidence


Slenyto® efficacy was demonstrated in a randomized placebo-controlled, multi-center confirmatory, Phase III trial conducted in 4 countries including 125 pediatric ASD and SMS patients. Patients were aged 2-18 year old and were treated with either Slenyto® (60 patients) or placebo (65 patients) for a period of 13 weeks, followed by a long term follow up (91 weeks) in which all patients were treated with Slenyto® (total of 2 years) with additional 2 weeks placebo run-out period.

Slenyto study design

28.8% of participants had comorbid ADHD, and 12.8% participants had comorbid epilepsy. Prior ADHD treatment was reported by 10.4% of the participants, antidepressant by 8%, anti-epileptics by 6.4%, clonidine by 5.6%, and β-blockers by 0.8%.

The study was successfully completed demonstrating Slenyto® efficacy in improving children sleep variables (sleep onset, maintenance and total sleep time), children daytime behavior and parents well-being , both in the short- and long-term, demonstrating Slenyto® ability to provide patients with Good Nights and Better Days.  

Slenyto® Benefits

Slenyto improves Sleep latency, Sleep maintenance and Total Sleep Time rapidly & for the long term
Slenyto improves child’s externalizing behaviors (hyperactivity/inattention and conduct)
Slenyto improves parents/caregivers quality of life
Dose adjustable - 2mg, 5mg, 10mg 
Over 75% of patients responded, once dose adjusted
Benefit was similar in all age groups, from 2 to 18 years
Compliance was close to 100% throughout the study

Improves Sleep Onset latency, Sleep Maintenance and Total Sleep Time


Improves child’s externalizing behaviors (hyperactivity/inattention and conduct)


Improves parents/caregivers Quality of Life


Dose adjustable - 2mg, 5mg, 10mg 


Over 75% of patients responded, once dose adjusted


Benefit was similar in all age groups, from 2 to 18 years


Compliance was close to 100% throughout the study

Sleep Benefits

Slenyto®’s prolonged release properties improves both sleep initiation and sleep maintenance, resulting in increased total sleep time without early awakenings, in comparison to immediate release preparations which improve only sleep initiation and cause early awakenings. 

Slenyto® improves Total Sleep Time

Slenyto significantly improves Total Sleep Time (TST)

After dose optimization (week 52)

Slenyto® shortens Sleep Latency

Slenyto significantly shortens Sleep Latency

After dose optimization (week 52)

Slenyto® improves Sleep Maintenance

Slenyto improves sleep maintenance

After dose optimization (week 52)

Child Behavior Benefits

Better sleep leads to better behavior and social functioning


In children with abnormal hyperactivity score, sub‑population of 77% of the study cohort

Caregiver’s Benefit 

Alleviation of a child or adolescent sleep and behavior should also have a positive effect on their parents’ satisfaction with their treatment and overall Quality of Life. 

Slenyto® improves parents' satisfaction from child sleep

Slenyto improves parents satisfaction from child sleep

Parents’ satisfaction with their child's sleep increased significantly with Slenyto® by an average of almost 2 units on a scale of 1-5

Slenyto® improves caregiver’s Quality of Life (QoL)

Slenyto improves caregiver’s Quality of Life (QoL)

Almost 50% of caregivers experienced a clinically relevant improvement with Slenyto® of 10% over baseline QoL score at 6 and 12 month

References: 1. Gringras P, et al., J Am Acad Child Adolesc Psychiatry, 2017; 56(11):948-957.e4; 2. Maras A., et al.,J Child Adolesc Psychopharmacol, 2018;doi: 10.1089/cap.2018.0020; 3. Gringras., P et al.,BMJ , 2012; 345:e6664; 4. Schroder, C. M. et al., Expert Opin Pharmacother. 2021;22(18):2445-2454; 5.

bottom of page